NICE is unable to make a recommendation on ciltacabtagene autoleucel (Carvykti) for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. We will review this decision if the company decides to make a submission....

Texto completo

NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....

Texto completo

El Mieloma Múltiple es un tipo de neoplasia hematológica maligna incurable en la actualidad, que se caracteriza por la afección y multiplicación sin control de células plasmáticas en la médula ósea con su consecuente secreción de una proteína monoclonal y síntomas como anemia, hipercalcemia, f...

Texto completo